Hillsdale Investment Management Inc. continued to hold its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) during the first quarter, Holdings Channel reports. The firm owned 117,400 shares of the medical instruments supplier’s stock at the end of the first quarter. Hillsdale Investment Management Inc.’s holdings in OraSure Technologies were worth $1,518,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the company. Stevens Capital Management LP raised its stake in shares of OraSure Technologies by 15.9% in the third quarter. Stevens Capital Management LP now owns 14,514 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 1,995 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of OraSure Technologies during the fourth quarter worth about $124,000. Eagle Global Advisors LLC acquired a new stake in shares of OraSure Technologies during the third quarter worth about $131,000. Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of OraSure Technologies by 11.4% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 16,650 shares of the medical instruments supplier’s stock worth $133,000 after buying an additional 1,710 shares during the last quarter. Finally, Profund Advisors LLC acquired a new stake in shares of OraSure Technologies during the first quarter worth about $137,000. Institutional investors and hedge funds own 79.51% of the company’s stock.
Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) traded up 1.18% on Friday, hitting $14.52. The stock had a trading volume of 707,494 shares. The firm’s 50-day moving average price is $13.45 and its 200 day moving average price is $10.55. The firm has a market cap of $838.70 million, a P/E ratio of 27.82 and a beta of 1.44. OraSure Technologies, Inc. has a 12 month low of $5.57 and a 12 month high of $15.72.
OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.04. The business had revenue of $32.55 million during the quarter, compared to analysts’ expectations of $31.19 million. OraSure Technologies had a net margin of 15.38% and a return on equity of 11.64%. The company’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.04 earnings per share. Analysts anticipate that OraSure Technologies, Inc. will post $0.42 EPS for the current fiscal year.
WARNING: This news story was originally published by Mideast Time and is owned by of Mideast Time. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.mideasttime.com/hillsdale-investment-management-inc-has-1518000-position-in-orasure-technologies-inc-osur/1709049.html.
A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered OraSure Technologies from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 1st. Jefferies Group LLC increased their price target on OraSure Technologies from $12.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, May 4th. Canaccord Genuity set a $12.00 price target on OraSure Technologies and gave the stock a “buy” rating in a research note on Thursday, February 9th. Finally, Raymond James Financial, Inc. upgraded OraSure Technologies from a “market perform” rating to an “outperform” rating and set a $11.25 price target for the company in a research note on Thursday, February 9th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $12.04.
In other news, EVP Anthony Zezzo II sold 115,000 shares of the business’s stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $14.70, for a total transaction of $1,690,500.00. Following the completion of the sale, the executive vice president now owns 260,410 shares of the company’s stock, valued at $3,828,027. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Douglas A. Michels sold 209,800 shares of the business’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $15.01, for a total transaction of $3,149,098.00. Following the sale, the chief executive officer now directly owns 782,025 shares of the company’s stock, valued at approximately $11,738,195.25. The disclosure for this sale can be found here. Insiders have sold 870,058 shares of company stock valued at $12,937,597 in the last three months. Corporate insiders own 7.80% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.